Association of EGFR kinase domain mutations with uncontrolled cell growth, proliferation, and migration have been reported in 32.9% of NSCLC and have proposed EGFR gene as the major oncogenic drug target in lung cancer [45,80,81,82]. The gene discussed is EGFR; the disease is lung carcinoma.